4502 On Other Exchanges
Symbol
Exchange
4502 is not on other exchanges.

takeda pharmaceutical co ltd (4502) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. The company operates through three segments: Ethical Drugs, Consumer Healthcare, and Other. It provides products in various therapeutic areas, including gastroenterology, oncology, central nervous system, cardiovascular and metabolic, vaccines, and others. The company has an agreement with Altos Therapeutics LLC for the development of ATC-1906 compound as an oral dopamine D2/D3 receptor antagonist that addresses the symptoms of nausea and vomiting in GP patients; and a research collaboration with Affilogic to explore Nanofitins platform in therapies targeting the central nervous system. It also has a collaboration with Arcturus Therapeutics, Inc. to develop RNA-based therapeutics for the treatment of NASH and other gastrointestinal related disorders utilizing Arcturus’ therapeutic delivery platform LUNAR and UNA Oligomer chemistry. In addition, the company has a collaboration with Maverick Therapeutics Inc. to develop Maverick’s T-cell engagement platform to improve the utility of T-cell redirection therapy for the treatment of cancer; and development and commercialization agreement with Ovid Therapeutics for investigational selective of TAK-935, a CH24H inhibitor in rare paediatric epilepsies. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥495.0M
Corporate Strategy Officer and Director
Total Annual Compensation: ¥85.0M
Chief Medical & Scientific Officer and Direct...
Total Annual Compensation: ¥263.0M
Compensation as of Fiscal Year 2016.
takeda pharmaceutical co ltd
Takeda Pharmaceutical Announces Partnership with Ovid Therapeutics to Develop Epilepsy Candidate

Takeda Pharmaceutical and Ovid Therapeutics have entered into a development and commercialisation agreement for Takeda's investigational highly selective CH24H inhibitor, TAK-935, in rare paediatric epilepsies. Based on the terms of the agreement, Takeda has been issued an equity stake in Ovid, and will be eligible for milestone payments based on regulatory development of the candidate. The companies will equally split development and commercialisation costs, and if the candidate is commercialised will also equally share profits. Furthermore, Takeda will be responsible for commercialisation of TAK-935 in Japan, with the option to also lead in Asia and certain other markets. Meanwhile, Ovid will be responsible for clinical development and commercialisation of the candidate in the US, Europe, Canada, and Israel. The collaboration initiatives will be guided by an integrated team from both companies, and additional central nervous system orphan disease indications could be investigated if both companies agree to pursue new uses. The strategic partnership will enable Takeda to build on Ovid's expertise in developing drugs for rare neurological diseases.

Maverick Therapeutics Inc. and Takeda Pharmaceutical Company Limited Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

Maverick Therapeutics Inc. and Takeda Pharmaceutical Company Limited announced that they have entered a collaboration to develop Maverick’s T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer. The $125 million of funding includes an upfront option, equity and research and development funding payments, and provides Takeda the exclusive right to purchase Maverick after five years for an undisclosed sum. Maverick was founded in 2016.

Takeda Seeks Acquisitions

Takeda Pharmaceutical Company Limited (TSE:4502) is looking for acquisitions. James Kehoe, Chief Financial Officer of Takeda Pharmaceutical said, "said that the Japanese company's acquisition spree may continue."

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4502.
View Industry Companies
 

Industry Analysis

4502

Industry Average

Valuation 4502 Industry Range
Price/Earnings 21.7x
Price/Sales 1.9x
Price/Book 1.8x
Price/Cash Flow 11.7x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.